RATIONALE: Sazetidine-A is a selective α4β2 nicotinic receptor desensitizing agent and partial agonist. It has been shown in previous studies to significantly reduce nicotine self-administration in rats after acute or repeated injections. However, the effects of continuous chronic infusions of sazetidine-A on maintenance of nicotine self-administration and relapse after abstinence have yet to be examined. OBJECTIVES: This study evaluated the efficacy of continuous sazetidine-A infusions (sc) over a period of 4 weeks to reduce nicotine self-administration in male and female Sprague-Dawley rats. METHODS: Sazetidine-A was administered via Alzet osmotic minipumps to young adult female and male rats at doses of 0, 2 or 6 mg/kg/day for 4 weeks. The effects of sazetidine-A on IV nicotine self-administration were examined in repeated 3-h sessions over the first 2 weeks of infusion followed by 1 week of forced abstinence from nicotine and 1 week of resumed nicotine access. RESULTS: The 6 mg/kg/day sazetidine-A dose significantly reduced overall nicotine self-administration compared with vehicle control across the sessions for both male (p < 0.001) and female (p < 0.05) rats. The lower 2 mg/kg/day sazetidine-A infusion dose was effective in reducing nicotine self-administration for male (p < 0.001), but not female rats. No attenuation in sazetidine-A effectiveness was seen over the course of the 4-week treatment. In the vehicle control group, male rats self-administered significantly (p < 0.001) more nicotine than females. CONCLUSIONS: The continuing effectiveness of sazetidine-A in reducing nicotine self-administration in both male and female rats supports its promise as a new treatment to help people successfully quit smoking.
RATIONALE: Sazetidine-A is a selective α4β2 nicotinic receptor desensitizing agent and partial agonist. It has been shown in previous studies to significantly reduce nicotine self-administration in rats after acute or repeated injections. However, the effects of continuous chronic infusions of sazetidine-A on maintenance of nicotine self-administration and relapse after abstinence have yet to be examined. OBJECTIVES: This study evaluated the efficacy of continuous sazetidine-A infusions (sc) over a period of 4 weeks to reduce nicotine self-administration in male and female Sprague-Dawley rats. METHODS:Sazetidine-A was administered via Alzet osmotic minipumps to young adult female and male rats at doses of 0, 2 or 6 mg/kg/day for 4 weeks. The effects of sazetidine-A on IV nicotine self-administration were examined in repeated 3-h sessions over the first 2 weeks of infusion followed by 1 week of forced abstinence from nicotine and 1 week of resumed nicotine access. RESULTS: The 6 mg/kg/day sazetidine-A dose significantly reduced overall nicotine self-administration compared with vehicle control across the sessions for both male (p < 0.001) and female (p < 0.05) rats. The lower 2 mg/kg/day sazetidine-A infusion dose was effective in reducing nicotine self-administration for male (p < 0.001), but not female rats. No attenuation in sazetidine-A effectiveness was seen over the course of the 4-week treatment. In the vehicle control group, male rats self-administered significantly (p < 0.001) more nicotine than females. CONCLUSIONS: The continuing effectiveness of sazetidine-A in reducing nicotine self-administration in both male and female rats supports its promise as a new treatment to help people successfully quit smoking.
Authors: E C Donny; A R Caggiula; P P Rowell; M A Gharib; V Maldovan; S Booth; M M Mielke; A Hoffman; S McCallum Journal: Psychopharmacology (Berl) Date: 2000-09 Impact factor: 4.530
Authors: Nadia Chaudhri; Anthony R Caggiula; Eric C Donny; Sheri Booth; Maysa A Gharib; Laure A Craven; Shannon S Allen; Alan F Sved; Kenneth A Perkins Journal: Psychopharmacology (Berl) Date: 2005-01-29 Impact factor: 4.530
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: E D Levin; E C Westman; R M Stein; E Carnahan; M Sanchez; S Herman; F M Behm; J E Rose Journal: J Clin Psychopharmacol Date: 1994-02 Impact factor: 3.153
Authors: A H Rezvani; D Eddins; S Slade; D S Hampton; N C Christopher; A Petro; K Horton; M Johnson; E D Levin Journal: Neuroscience Date: 2008-04-16 Impact factor: 3.590
Authors: Sherry A McKee; Emily L R Harrison; Stephanie S O'Malley; Suchitra Krishnan-Sarin; Julia Shi; Jeanette M Tetrault; Marina R Picciotto; Ismene L Petrakis; Naralys Estevez; Erika Balchunas Journal: Biol Psychiatry Date: 2009-02-27 Impact factor: 13.382
Authors: Rodolfo J Flores; Joseph A Pipkin; Kevin P Uribe; Adriana Perez; Laura E O'Dell Journal: Behav Brain Res Date: 2016-04-06 Impact factor: 3.332
Authors: Robert J Wickham; Eric J Nunes; Shannon Hughley; Phillip Silva; Sofia N Walton; Jinwoo Park; Nii A Addy Journal: Neuropharmacology Date: 2017-09-21 Impact factor: 5.250
Authors: Edward D Levin; Corinne Wells; Joshua E Johnson; Amir H Rezvani; Frank P Bymaster; Jed E Rose Journal: Eur J Pharmacol Date: 2015-06-20 Impact factor: 4.432
Authors: Ramón Sotomayor-Zárate; Katia Gysling; Usoa E Busto; Bruce K Cassels; Lutske Tampier; María Elena Quintanilla Journal: Psychopharmacology (Berl) Date: 2013-01-24 Impact factor: 4.530
Authors: G Patrick Hussmann; Kristen E DeDominicis; Jill R Turner; Robert P Yasuda; Jacquelyn Klehm; Patrick A Forcelli; Yingxian Xiao; Janell R Richardson; Niaz Sahibzada; Barry B Wolfe; Jon Lindstrom; Julie A Blendy; Kenneth J Kellar Journal: J Neurochem Date: 2014-02-07 Impact factor: 5.372